Divalproex Sodium
Product Images NDC 68151-1164

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68151-1164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl681511164)

Divalproex Sodium is a medication that comes in the form of a 125 mg delayed-release tablet. It is manufactured by SUN under the code MEG and has JKM3668A as its identification number. The tablet has an expiration date of November 2014 and the package was produced on May 19th, 2014 as indicated by the code W051914iml. This medication is only available with a prescription (Rx only) and no additional information is provided.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

This appears to be a figure caption of two studies involving the drugs PBO and DVPX. The studies are identified as Study 1 and Study 2, with each study being evaluated using a different rating scale - the YMRS for Study 1 and the MRS for Study 2. The context and results of the studies are not provided.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

This appears to be a graph or chart showing the results of a study or trial. It includes percentages related to the rate of CPS (not clear what this stands for) and a scale that ranges from -100% to 100%. Two different treatments or conditions are compared (DVPX and Placebo) and their effects on patient improvement, worsening, or no change are shown. More context is needed to understand the full meaning of this chart.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

This text seems to be a figure or a table containing the mean 4-week migraine rates for placebo and DVPX in two different studies (Study 1 and Study 2). However, without further context or data, it is not possible to determine the values represented by "Placebo" and "DVPX".*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.